CA3219490A1 - Substituted carbamate macrocyclic compounds and related methods of treatment - Google Patents

Substituted carbamate macrocyclic compounds and related methods of treatment Download PDF

Info

Publication number
CA3219490A1
CA3219490A1 CA3219490A CA3219490A CA3219490A1 CA 3219490 A1 CA3219490 A1 CA 3219490A1 CA 3219490 A CA3219490 A CA 3219490A CA 3219490 A CA3219490 A CA 3219490A CA 3219490 A1 CA3219490 A1 CA 3219490A1
Authority
CA
Canada
Prior art keywords
alkylene
cycloalkyl
alkyl
aryl
membered heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3219490A
Other languages
English (en)
French (fr)
Inventor
Lewis D. Pennington
Younggi Choi
Hoan Huynh
Brian M. Aquila
Ingo Andreas Mugge
Yuan HU
James R. Woods
Brian Kenneth Raymer
Jorg Martin BENTZIEN
Jonathan Ward LEHMANN
Michael R. Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Inc
Original Assignee
Alkermes Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc filed Critical Alkermes Inc
Publication of CA3219490A1 publication Critical patent/CA3219490A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA3219490A 2021-05-26 2022-05-25 Substituted carbamate macrocyclic compounds and related methods of treatment Pending CA3219490A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163193256P 2021-05-26 2021-05-26
US63/193,256 2021-05-26
PCT/US2022/030841 WO2022251304A1 (en) 2021-05-26 2022-05-25 Substituted carbamate macrocyclic compounds and related methods of treatment

Publications (1)

Publication Number Publication Date
CA3219490A1 true CA3219490A1 (en) 2022-12-01

Family

ID=82156598

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3219490A Pending CA3219490A1 (en) 2021-05-26 2022-05-25 Substituted carbamate macrocyclic compounds and related methods of treatment

Country Status (8)

Country Link
US (1) US20240174689A1 (https=)
EP (1) EP4347604B1 (https=)
JP (1) JP7833486B2 (https=)
CN (1) CN117651703A (https=)
AU (1) AU2022280804A1 (https=)
CA (1) CA3219490A1 (https=)
ES (1) ES3057101T3 (https=)
WO (1) WO2022251304A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250155550A (ko) 2023-03-16 2025-10-30 다케다 야쿠힌 고교 가부시키가이샤 매크로시클릭 헤테로시클 화합물 및 이의 용도
WO2025124698A1 (en) 2023-12-12 2025-06-19 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
TW202542165A (zh) 2023-12-19 2025-11-01 瑞士商愛杜西亞製藥有限公司 大環食慾素激動劑

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
CA2930693A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior Unversity Methods of treating heart failure with agonists of hypocretin receptor 2
PE20161064A1 (es) 2013-12-12 2016-10-28 Univ Tsukuba Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
WO2015147240A1 (ja) 2014-03-28 2015-10-01 国立大学法人筑波大学 敗血症の予防治療剤
PL3411358T3 (pl) 2016-02-04 2022-02-28 Takeda Pharmaceutical Company Limited Podstawiony związek piperydynowy i jego zastosowanie
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US20200207734A1 (en) * 2017-08-03 2020-07-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
WO2020167701A1 (en) * 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists
FI4065585T3 (fi) 2019-11-25 2025-09-26 Alkermes Inc Substituoituja makrosyklisiä yhdisteitä ja niihin liittyviä hoitomenetelmiä
WO2022051583A1 (en) * 2020-09-03 2022-03-10 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonists
US12006330B2 (en) * 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) * 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment

Also Published As

Publication number Publication date
EP4347604B1 (en) 2025-12-03
JP7833486B2 (ja) 2026-03-19
JP2024520396A (ja) 2024-05-24
WO2022251304A1 (en) 2022-12-01
CN117651703A (zh) 2024-03-05
EP4347604C0 (en) 2025-12-03
ES3057101T3 (en) 2026-02-26
AU2022280804A1 (en) 2023-11-30
US20240174689A1 (en) 2024-05-30
WO2022251304A8 (en) 2023-01-05
EP4347604A1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
EP4329877B1 (en) Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity
US12441710B2 (en) Substituted piperidino compounds and related methods of treatment
CA3219506A1 (en) Substituted fused bicyclic macrocyclic compounds and related methods of treatment
CA3219490A1 (en) Substituted carbamate macrocyclic compounds and related methods of treatment
WO2007017094A1 (en) Substituted benzyloxy-phenylmethylcarbamate derivatives
US20250223260A1 (en) Substituted Pyrrolidinyl And Piperidinyl Compounds And Related Methods Of Treatment
WO2023249871A1 (en) Substituted pyrrolidinyl and piperidinyl compounds and related methods of treatment
EP4543446A1 (en) Substituted fused bicyclic compounds and related methods of treatment
EP4543447A2 (en) Substituted fused bicyclic compounds and related methods of treatment
HK40099265B (en) Substituted piperidino compounds and related methods of treatment
HK40099265A (en) Substituted piperidino compounds and related methods of treatment

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250516

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250516

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260205

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260205

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260206

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260206

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260225

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260225

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260225